Fighting sarcoidosis as well as other rare diseases.

Episode 17 aTyr Pharma CEO Sanjay Shukla talks about how a new drug could be the answer for many sarc fighters!

September 14, 2020

aTyr Pharma is working on a drug that could be the answer for many Sarc Fighters -- especially that large percentage fighting pulmonary sarc - or sarcoidosis of the lungs.  aTyr CEO Sanjay Shukla joins me for this podcast to talk about how the drug interacts with a patient's body to prevent sarc from damaging the tissues and causing the damage we are so familiar with.  


The drug, called aTyr1923 is in the second stage of clinical trials.  It has shown great promise in mice, but the results in humans are still undetermined.  Why is aTyr willing to take on such an expensive and risky undertaking?  How do you try to cure a disease that has no known cause?  And why focus all your efforts on a relatively small number of potential patients?  I asked Sanjay all those questions, and he had some enlightening answers!

More about aTyr

Clinical Trials with Atyr1923

Sanjay Shukla Bio


Do you like the official song for the Sarc Fighter podcast?  It's also an FSR fundraiser!

If you would like to donate in honor of Mark Steier and the song, Zombie, Here is a link to his KISS account.  (Kick In to Stop Sarcoidosis)  100-percent of the money goes to the Foundation.

You can listen on You Tube as well.


The Foundation for Sarcoidosis Research

FSR Summits 2020

Donate to my KISS (Kick In to Stop Sarcoidosis) fund for FSR

My story on Television

email me

Sarc Fighter Facebook Page

Sarc Fighter on Instagram

Cycling with Sarcoidosis